DDInter425 DDInter1147
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Cobimetinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib